Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 0.47 |
| ▸ | AKT1 | P31749 | 13/20 | 0.47 |
| ▸ | MTOR | P42345 | 10/20 | 0.47 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.42 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2397730 | 0.88 | PIK3CA (0.50) | PIK3CAAKT1MTORMAP3K12 | |
| SCHEMBL12313600 | 0.85 | PIK3CA (0.51) | PIK3CAAKT1MTORMAP3K12 | |
| SCHEMBL2397509 | 0.84 | PIK3CA (0.47) | PIK3CAAKT1MTORMAP3K12PIK3R1 | |
| SCHEMBL12489220 | 0.81 | PIK3CA (0.48) | PIK3CAAKT1MTORMAP3K12 | |
| SCHEMBL2397720 | 0.81 | PIK3CA (0.47) | PIK3CAAKT1MTORMAP3K12 | |
| SCHEMBL1497717 | 0.80 | PIK3CA (0.50) | PIK3CAAKT1MTORMAP3K12PIK3R1 | |
| SCHEMBL1497377 | 0.80 | PIK3CA (0.49) | PIK3CAAKT1MTORMAP3K12 | |
| SCHEMBL1497596 | 0.80 | PIK3CA (0.45) | PIK3CAAKT1MTORMAP3K12PIK3R1 | |
| SCHEMBL2399183 | 0.80 | PIK3CA (0.45) | PIK3CAAKT1MTORMAP3K12PIK3R1 | |
| SCHEMBL2393329 | 0.80 | PIK3CA (0.46) | PIK3CAAKT1MTORMAP3K12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| WO-2011031896-A2 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PIK3CA, PIK3CB, PIK3C2B | PIK3CA 1/4885AKT1 27/4885MTOR 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.